OXLUMO
NDC 71336-1002, lumasiran, injection, solution, from Alnylam Pharmaceuticals, Inc..
- Product NDC
- 71336-1002
- Status
- Listed
- Labeler
- Alnylam Pharmaceuticals, Inc.
- Dosage form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- NDA
- Application
- NDA214103
- DEA schedule
- None
curl https://api.healthcare.dev/v1/drugs/ndc/71336-1002 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- LUMASIRAN SODIUM94.5 mg/.5mL
| Package NDC | NDC-11 | Package |
|---|---|---|
| 71336-1002-1 | 71336100201 | 1 VIAL, SINGLE-USE in 1 CARTON (71336-1002-1) / .5 mL in 1 VIAL, SINGLE-USE |
Linked data
RxNorm, label and prices
RxNorm concepts
Related lookups
FDA label sections
GET /v1/drugs/labels/16985a31-f5e4-4557-9266-fc78d4bc5055Medicare Part B payment limits (ASP)
GET /v1/drugs/asp?ndc=71336-1002
Use it
Look up 71336-1002 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/71336-1002 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 71336-1002. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.